XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2018
Sep. 30, 2017
CURRENT ASSETS    
Cash and cash equivalents $ 69,805,117 $ 24,838,567
Accounts receivable 16,288 67,797
Prepaid expenses 744,246 867,363
Other current assets 357,989 1,359,638
Short term investments 21,736,820 40,769,539
TOTAL CURRENT ASSETS 92,660,460 67,902,904
Property and equipment, net 14,582,313 15,513,019
Intangible assets, net 19,614,224 20,464,439
Other assets 141,918 141,918
TOTAL ASSETS 126,998,915 104,022,280
CURRENT LIABILITIES    
Accounts payable 1,810,431 4,076,514
Accrued expenses 4,127,208 4,564,507
Accrued payroll and benefits 918,226 3,399,679
Deferred rent 440,580 440,580
Deferred revenue 1,565,000 5,269,741
Derivative liabilities   695,114
Note Payable 216,027 208,506
Other current liabilities 46,407 46,407
TOTAL CURRENT LIABILITIES 9,123,879 18,701,048
LONG-TERM LIABILITIES    
Deferred rent, net of current portion 1,744,863 1,929,052
Note Payable, net of current portion 2,215,091 2,325,018
Other non-current liabilities 200,000 200,000
TOTAL LONG-TERM LIABILITIES 4,159,954 4,454,070
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:    
Common stock, $0.001 par value; 145,000,000 shares authorized; 87,570,398 and 74,785,426 shares issued and outstanding as of March 31, 2018 and September 30, 2017, respectively 179,940 167,155
Additional paid-in capital 574,963,592 514,037,301
Accumulated other comprehensive income (loss) 25,265 33,232
Accumulated deficit (460,898,527) (432,815,338)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity 114,270,270 81,422,350
Noncontrolling interest (555,188) (555,188)
TOTAL STOCKHOLDERS’ EQUITY 113,715,082 80,867,162
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 126,998,915 $ 104,022,280